These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
222 related items for PubMed ID: 35039353
21. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus]. Qiu JL, Luo SM, Yin WF, Li X, Zhou ZG. Zhonghua Yi Xue Za Zhi; 2023 Jan 07; 103(1):38-41. PubMed ID: 36594136 [Abstract] [Full Text] [Related]
22. Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma. Kichloo A, Albosta MS, McMahon S, Movsesian K, Wani F, Jamal SM, Aljadah M, Singh J. J Investig Med High Impact Case Rep; 2020 Jan 07; 8():2324709620951339. PubMed ID: 32830561 [Abstract] [Full Text] [Related]
23. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma. Wu L, Li B. Diabetes Metab Syndr Obes; 2021 Jan 07; 14():753-757. PubMed ID: 33628041 [Abstract] [Full Text] [Related]
24. Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer. Ichihara S, Kunishige M, Kadota N, Okano Y, Machida H, Hatakeyama N, Naruse K, Shinohara T, Takeuchi E. Thorac Cancer; 2023 Jan 07; 14(1):81-84. PubMed ID: 36411591 [Abstract] [Full Text] [Related]
25. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I. Immunotherapy; 2017 Sep 07; 9(10):797-804. PubMed ID: 28877632 [Abstract] [Full Text] [Related]
30. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature. Ning P, Liu S, Cao H. J Med Case Rep; 2024 Jan 22; 18(1):51. PubMed ID: 38247005 [Abstract] [Full Text] [Related]
31. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. Gunjur A, Klein O, Kee D, Cebon J. J Immunother Cancer; 2019 Sep 05; 7(1):241. PubMed ID: 31488221 [Abstract] [Full Text] [Related]